TriangleViCToRy (NCT05609994)
ViCToRy trial for Low Grade Glioma of Brain (NCT05609994). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for recurrent IDH1 mutant lower grade glioma, a brain tumor, in adults at the first recurrence.
The idea: pair two treatments. Vorasidenib, a daily pill taken for up to 14 four week cycles, blocks the mutant IDH1 and IDH2 enzymes. After two cycles, a tumor specific peptide vaccine is added, given under the skin. Servier is listed as a collaborator.
The trial plans 48 patients and begins with a safety lead-in. At Duke University in Durham, Katherine Peters leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.